VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor
VSTM Verastem Oncology doses first patient in target-d 203 phase 2 registration-directed trial of vs-7375 oral kras g12d (on/off) inhibitor for kras g12d-mutated metastatic colorectal cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.